Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes Mellitus

Although hyperglycemia is a key therapeutic focus in the management of patients with type 2 diabetes mellitus (T2DM), many patients experience sub-optimal glycemic control. Current glucose-lowering agents involve the targeting of various body organs. Sodium glucose co-transporter type 2 (SGLT2) inhi...

Descripción completa

Detalles Bibliográficos
Autor principal: Bays, Harold
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3889318/
https://www.ncbi.nlm.nih.gov/pubmed/24142577
http://dx.doi.org/10.1007/s13300-013-0042-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3889318/
https://www.ncbi.nlm.nih.gov/pubmed/24142577
http://dx.doi.org/10.1007/s13300-013-0042-y

Ejemplares similares